{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:20:59Z","timestamp":1790709659573,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.alit.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:30:02Z","timestamp":1655944202000},"page":"498-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough"],"prefix":"10.1016","volume":"71","author":[{"given":"Akio","family":"Niimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Arano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Muccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2022.05.006_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.chest.2017.10.016","article-title":"Classification of cough as a symptom in adults and management algorithms: CHEST Guideline and Expert Panel Report","volume":"153","author":"Irwin","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.alit.2022.05.006_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.chest.2017.05.038","article-title":"Risk factors for chronic cough among 14,669 individuals from the general population","volume":"152","author":"\u00c7olak","year":"2017","journal-title":"Chest"},{"issue":"Suppl 63","key":"10.1016\/j.alit.2022.05.006_bib3","first-page":"PA3327","article-title":"Prevalence of chronic cough, patient characteristics and health outcomes among UK adults [ERS abstract]","volume":"54","author":"Mcgarvey","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.05.006_bib4","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1016\/j.jaip.2021.07.022","article-title":"Prevalence and burden of chronic cough in the United States","volume":"9","author":"Meltzer","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.05.006_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2332\/allergolint.11-OA-0368","article-title":"Frequency of persistent cough and trends in seeking medical care and treatment-results of an internet survey","volume":"61","author":"Fujimura","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.05.006_bib6","doi-asserted-by":"crossref","first-page":"e000832","DOI":"10.1136\/bmjresp-2020-000832","article-title":"Web-based survey to evaluate the prevalence of chronic and subacute cough and patient characteristics in Japan","volume":"8","author":"Tobe","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.alit.2022.05.006_bib7","doi-asserted-by":"crossref","first-page":"e000764","DOI":"10.1136\/bmjresp-2020-000764","article-title":"Disease burden and quality of life of patients with chronic cough in Japan: a population-based cross-sectional survey","volume":"8","author":"Kubo","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.alit.2022.05.006_bib8","doi-asserted-by":"crossref","first-page":"1901136","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.05.006_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.resinv.2021.01.007","article-title":"The Japanese Respiratory Society guidelines for the management of cough and sputum (digest edition)","volume":"59","author":"Mukae","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.alit.2022.05.006_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/IJGM.S8167","article-title":"Cough and asthma diagnosis: physicians' diagnosis and treatment of patients complaining of acute, subacute and chronic cough in rural areas of Japan","volume":"3","author":"Yamasaki","year":"2010","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.alit.2022.05.006_bib11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3109\/02770903.2013.823444","article-title":"Cough variant and cough-predominant asthma are major causes of persistent cough: a multicenter study in Japan","volume":"50","author":"Niimi","year":"2013","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.alit.2022.05.006_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-9974-3-1","article-title":"Prevalence and clinical manifestations of gastro-oesophageal reflux-associated chronic cough in the Japanese population","volume":"3","author":"Matsumoto","year":"2007","journal-title":"Cough"},{"key":"10.1016\/j.alit.2022.05.006_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00408-020-00359-w","article-title":"Obesity predicts treatment response to proton pump inhibitor therapy in patients with chronic cough","volume":"198","author":"Descazeaux","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.alit.2022.05.006_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7812\/TPP\/20.022","article-title":"Prevalence and characteristics of chronic cough in adults identified by administrative data","volume":"24","author":"Zeiger","year":"2020","journal-title":"Perm J"},{"key":"10.1016\/j.alit.2022.05.006_bib15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.alit.2019.04.011","article-title":"Clinical impact of gastroesophageal reflux disease in patients with subacute\/chronic cough","volume":"68","author":"Kanemitsu","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.05.006_bib16","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaip.2019.04.012","article-title":"What is chronic cough? Terminology","volume":"7","author":"McGarvey","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.05.006_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/rccm.200607-892OC","article-title":"Opiate therapy in chronic cough","volume":"175","author":"Morice","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2022.05.006_bib18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1378\/chest.15-1271","article-title":"Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial","volume":"149","author":"Vertigan","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.alit.2022.05.006_bib19","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1378\/chest.13-0490","article-title":"Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis","volume":"144","author":"Yancy","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.alit.2022.05.006_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00408-021-00438-6","article-title":"Coming soon: the first-ever drug(s) for refractory chronic cough","volume":"199","author":"Dicpinigaitis","year":"2021","journal-title":"Lung"},{"key":"10.1016\/j.alit.2022.05.006_bib21","author":"Kyorin Pharmaceutical Co., Ltd.,"},{"key":"10.1016\/j.alit.2022.05.006_bib22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","article-title":"Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials","volume":"399","author":"McGarvey","year":"2022","journal-title":"Lancet"},{"issue":"Suppl 110","key":"10.1016\/j.alit.2022.05.006_bib23","first-page":"5","article-title":"Medical history in patients with refractory or unexplained chronic cough (EAACI abstract 345)","volume":"76","author":"Dicpinigaitis","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.05.006_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1183\/23120541.00284-2020","article-title":"Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough","volume":"6","author":"Muccino","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.alit.2022.05.006_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.alit.2016.02.014","article-title":"Gastroesophageal dysmotility is associated with the impairment of cough-specific quality of life in patients with cough variant asthma","volume":"65","author":"Kanemitsu","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.05.006_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620915155","article-title":"Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough","volume":"14","author":"Martin Nguyen","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.alit.2022.05.006_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2022.05.006_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-540-79842-2_16","article-title":"Clinical cough IV:what is the minimal important difference for the Leicester Cough Questionnaire?","volume":"187","author":"Raj","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.alit.2022.05.006_bib29","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1126\/science.1118435","article-title":"ATP signaling is crucial for communication from taste buds to gustatory nerves","volume":"310","author":"Finger","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.alit.2022.05.006_bib30","doi-asserted-by":"crossref","first-page":"2100725","DOI":"10.1183\/13993003.00725-2021","article-title":"Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough","volume":"59","author":"Niimi","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.05.006_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211049743","article-title":"Validation of a visual analog scale for assessing cough severity in patients with chronic cough","volume":"15","author":"Martin Nguyen","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.alit.2022.05.006_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00408-021-00437-7","article-title":"Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-receptor antagonist gefapixant","volume":"199","author":"Morice","year":"2021","journal-title":"Lung"},{"key":"10.1016\/j.alit.2022.05.006_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1183\/23120541.00160-2021","article-title":"Prevalence, incidence and characteristics of chronic cough among adults from the Canadian Longitudinal Study on Aging","volume":"7","author":"Satia","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.alit.2022.05.006_bib34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cpdd.1047","article-title":"Assessment of pharmacokinetic interaction between gefapixant (MK-7264), a P2X3 receptor antagonist, and the OATP1B1 drug transporter substrate pitavastatin","volume":"11","author":"McCrea","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.alit.2022.05.006_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/cpdd.988","article-title":"Assessment of the effect of pyrimethamine, a potent inhibitor of multidrug and toxin extrusion protein 1\/2k, on the pharmacokinetics of gefapixant (MK-7264), a P2X3 receptor antagonist","volume":"11","author":"Nussbaum","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Suppl 65","key":"10.1016\/j.alit.2022.05.006_bib36","first-page":"OA1587","article-title":"The Leicester Cough Questionnaire in two phase 3 trials of gefapixant in chronic cough (ERS abstract).","volume":"58","author":"Birring","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.05.006_bib37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","article-title":"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial","volume":"8","author":"Smith","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893022000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893022000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:11:52Z","timestamp":1761156712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893022000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1323893022000478"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2022.05.006","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}